Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early renal cell cancer.

Yoshihiko Tomita1

  • 1Department of Urology, Course of Metabolic and Regenerative Medicine, Yamagata University, Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan. ytomita@med.id.yamagata-u.ac.jp

International Journal of Clinical Oncology
|March 2, 2006
PubMed
Summary

Renal cell cancer (RCC), a type of adenocarcinoma, is best treated with surgery. Early-stage RCC (T1 and T2) offers a good prognosis with tumor removal, while other treatments show limited benefit.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial.

Inflammation and regeneration·2026
Same author

Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.

Urologic oncology·2025
Same author

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab.

Cancer science·2025
Same author

Late-Onset Bone Metastasis 46 Years After Initial Surgery for Pheochromocytoma: A Case Report.

IJU case reports·2025
Same author

Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.

Nature medicine·2025
Same author

Polyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study).

Trials·2025

Area of Science:

  • Oncology
  • Urology

Background:

  • Renal cell cancer (RCC) originates in the proximal renal tubules and is classified as adenocarcinoma.
  • Current treatments like chemotherapy and radiotherapy are largely ineffective for RCC.

Purpose of the Study:

  • To discuss definitions, diagnosis, and treatment options for early-stage renal cell cancer (T1 and T2).
  • To highlight the effectiveness of surgical excision for organ-confined RCC.

Main Methods:

  • Review of existing literature on early-stage renal cell cancer (T1 and T2).
  • Discussion of diagnostic criteria and treatment modalities.

Main Results:

  • Surgical excision is the most effective treatment for RCC, particularly for organ-confined disease (T1 and T2).
  • Immunotherapy, including cytokine administration, may offer survival benefits in select patients.
  • Early-stage RCC (T1 and T2) removal often leads to a tumor-free status and good prognosis.

Conclusions:

  • Surgical removal is the primary and most effective treatment for organ-confined renal cell cancer (T1 and T2).
  • Further research into the definition and management of early RCC is warranted.
  • While immunotherapy shows promise, surgical intervention remains the cornerstone of treatment for localized RCC.

Related Experiment Videos